EOSCAPE-20^TM

Battery-powered, incredibly portable, and requiring virtually no maintenance, the EOSCAPE-20 System is designed for high-performance nucleic acid testing in diverse clinical environments including primary care facilities in low-resource settings.  The EOSCAPE-20 pioneers Wave 80’s unique bioassay technology for sample processing, analysis, and detection in a fully integrated enclosed cartridge. 

The EOSCAPE-20 HIV Assay, the first assay under development for the EOSCAPE-20 platform, measures HIV viral load in fingerstick/heelstick samples with a turnaround time of only four hours. Specifically designed to maximize the benefit of programs bringing antiretroviral therapy to underserved segments of the world’s 33 million HIV/AIDS patient population, the EOSCAPE-20 HIV Assay running on the EOSCAPE-20 System provides the vital semi-quantitative viral load data needed to guide “when-to-switch” clinical decisionmaking for patients undergoing antiretroviral therapy in the context of limited therapeutic options.

EOSCAPE-1500^TM

The EOSCAPE-1500 is a compact-footprint benchtop system with the same innovative cartridge bioassay technology as the EOSCAPE-20, but with support for venipuncture samples and higher throughput testing in a clinical laboratory or primary care setting  With a cost-effective one-patient/one-test operational model, the EOSCAPE-1500 is the ideal choice for healthcare facilities seeking to improve patient care and maximize revenue by bringing high-clinical-value nucleic acid testing in-house.  Assays under development for the EOSCAPE-1500 include ultrasensitive/quantitative HIV viral load.

EOSCAPE-1^TM

A rugged, handheld system for detecting biomarkers of malarial disease and other conditions. Currently under evaluation by the U.S. Special Operations Command.